City

Clinical trials near Houston, United States

Active studies with a listed research site in Houston, United States.

75active studies

39recruiting now

25countries represented

87largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 4

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Psoriatic Arthritis, Overweight or ObesityCondition

TirzepatideTreatment

Puerto Rico, United States55 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06864026See eligibility →

Recruiting nowPhase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Obesity, OverweightCondition

Macupatide, EloralintideTreatment

Argentina, Australia42 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07215559See eligibility →

Recruiting nowPhase 3

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Obesity, Overweight and/or ObesityCondition

PF-08653944, PlaceboTreatment

Brazil, Canada50 locations

PfizerSponsor

Updated 2026-09-04 · NCT07595549See eligibility →

Recruiting nowPhase 4

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Psoriasis, Overweight or ObesityCondition

TirzepatideTreatment

United States39 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06857942See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Japan87 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684235See eligibility →

Recruiting nowPhase 3

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Obesity, OverweightCondition

Maridebart Cafraglutide, PlaceboTreatment

Japan, Puerto Rico37 locations

AmgenSponsor

Updated 2026-09-03 · NCT07684144See eligibility →

Recruiting nowPhase 3

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Obesity, OverweightCondition

aleniglipron, aleniglipronTreatment

United States74 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-09-01 · NCT07654374See eligibility →

Recruiting nowPhase 3

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Obesity or OverweightCondition

Maridebart CafraglutideTreatment

Puerto Rico, United States45 locations

AmgenSponsor

Updated 2026-08-27 · NCT07575399See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Israel, Italy34 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672939See eligibility →

Recruiting nowPhase 2

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Type 2 DiabetesCondition

LY3457263, PlaceboTreatment

Canada, Germany60 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT06897475See eligibility →

Recruiting nowPhase 2

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

B-cell Acute Lymphoblastic Leukemia, ObesityCondition

IDEAL2 InterventionTreatment

United States16 locations

Etan OrgelSponsor

Updated 2026-08-19 · NCT05082519See eligibility →

Recruiting nowPhase 2

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)

Overweight, ObesityCondition

PF-08653945, PF-08653944Treatment

Canada, United States65 locations

PfizerSponsor

Updated 2026-08-17 · NCT07575932See eligibility →

Recruiting nowPhase 3

Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE)

Alcohol Use DisorderCondition

Semaglutide, PlaceboTreatment

United States19 locations

VA Office of Research and DevelopmentSponsor

Updated 2026-08-12 · NCT07218354See eligibility →

Recruiting nowNot applicable

Self-monitoring Focus Groups With Vibrant Lives Pasadena Participants

Obesity-Related Malignant NeoplasmCondition

Discussion, InterviewTreatment

United States1 locations

M.D. Anderson Cancer CenterSponsor

Updated 2026-08-11 · NCT04611087See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Obesity, OverweightCondition

Aleniglipron, PlaceboTreatment

United States71 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-08-10 · NCT07654361See eligibility →

Recruiting nowNot applicable

Postextubation Use of Noninvasive Respiratory Support in Severely Obese Patients

Obesity, Morbid, Extubation FailureCondition

Noninvasive ventilation alternating with high flow nasal cannula, High flow nasal cannulaTreatment

Mexico, United States5 locations

Rush University Medical CenterSponsor

Updated 2026-08-07 · NCT05918575See eligibility →

Recruiting nowPhase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Overweight, ObesityCondition

Macupatide, EloralintideTreatment

United States40 locations

Eli Lilly and CompanySponsor

Updated 2026-08-06 · NCT07589608See eligibility →

Recruiting nowPhase 2

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

ObesityCondition

NNC0662-0419, SemaglutideTreatment

Puerto Rico, United States25 locations

Novo Nordisk A/SSponsor

Updated 2026-07-10 · NCT07639021See eligibility →

Recruiting nowNot applicable

Adapting and Assessing the Feasibility of a Telehealth Diabetes Prevention Program for Hispanic Adolescents

Obesity and Type 2 DiabetesCondition

Fit24+Treatment

United States1 locations

Baylor College of MedicineSponsor

Updated 2026-07-07 · NCT06943001See eligibility →

Recruiting nowNot applicable

PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents

Obesity and Diabetes Mellitus, Type 2, Diabetes PreventionCondition

PATHS-UP Mobile Phone ApplicationTreatment

United States1 locations

Baylor College of MedicineSponsor

Updated 2026-07-07 · NCT06959901See eligibility →

Recruiting nowPhase 2

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

Overweight or Obesity and Elevated Liver FatCondition

Maridebart cafraglutide, PlaceboTreatment

United States23 locations

AmgenSponsor

Updated 2026-06-18 · NCT07441252See eligibility →

Recruiting nowPhase 1, Phase 2

Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

Alzheimer Dementia (AD)Condition

IL-2 (Aldesleukin), Semaglutide Plus IL-2Treatment

United States1 locations

The Methodist Hospital Research InstituteSponsor

Updated 2026-06-16 · NCT07651319See eligibility →

Recruiting nowPhase 2

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

Type 2 DiabetesCondition

icovamenib 100 mg, PlaceboTreatment

United States17 locations

Biomea Fusion Inc.Sponsor

Updated 2026-06-15 · NCT07502508See eligibility →

Recruiting nowNot applicable

Integrating Food Rx With Best Feeding Practices With EFNEP

Dietary Habits, Childhood ObesityCondition

BEST study - Nutrition education only, BEST study - Nutrition education and feeding practicesTreatment

United States1 locations

Baylor College of MedicineSponsor

Updated 2026-06-02 · NCT05881759See eligibility →

Recruiting nowNot applicable

Genetic Disorders of Obesity Program Database

Obesity, Childhood, Genetic DiseaseCondition

Intervention not listedTreatment

United States1 locations

Baylor College of MedicineSponsor

Updated 2026-05-12 · NCT05747976See eligibility →

Recruiting nowNot applicable

Reducing Obesity Through Play Among Toddlers: Tiny Steps to Health (TSHS) Study

Childhood ObesityCondition

Healthy Toddler Parent Group (HTPG), Families Understanding Nutrition and Physically Active Lifestyles (FUNPALs) PlaygroupTreatment

United States1 locations

University of HoustonSponsor

Updated 2026-05-05 · NCT06918821See eligibility →

Recruiting nowNot applicable

Utilization of a Peer-Based Approach for the Promotion of Physical Activity in Inactive Women

Obesity-Related Malignant NeoplasmCondition

Activity Monitor, Activity MonitorTreatment

United States1 locations

M.D. Anderson Cancer CenterSponsor

Updated 2026-05-04 · NCT05053113See eligibility →

Recruiting nowNot applicable

Determinants of Insulin Sensitivity by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis

Insulin Resistance, Polycystic Ovary SyndromeCondition

Intervention not listedTreatment

United States1 locations

Ali ChappellSponsor

Updated 2026-05-01 · NCT05950282See eligibility →

Recruiting nowNot applicable

Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery

Body Mass Index Greater Than or Equal to 30, Malignant Breast NeoplasmCondition

Negative Pressure Wound Therapy, Wound Care ManagementTreatment

United States1 locations

M.D. Anderson Cancer CenterSponsor

Updated 2026-04-21 · NCT04003038See eligibility →

Recruiting nowPhase 2

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

Cocaine Use DisorderCondition

Semaglutide, PlaceboTreatment

United States1 locations

The University of Texas Health Science Center, HoustonSponsor

Updated 2026-03-19 · NCT07227948See eligibility →

Recruiting nowEarly Phase 1

Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study

Diabetes, Prostate CancerCondition

TirzepatideTreatment

United States1 locations

M.D. Anderson Cancer CenterSponsor

Updated 2026-02-27 · NCT06759701See eligibility →

Recruiting nowPhase 2

Incretin Microdosing for Cardiometabolic Health in People With HIV

Weight GainCondition

Dose escalation to 2 mg semaglutide weekly then semaglutide microdosing at 0.5 mg weekly, Dose escalation to 2 mg semaglutide weekly then no semaglutideTreatment

United States1 locations

The University of Texas Health Science Center, HoustonSponsor

Updated 2026-02-18 · NCT07325500See eligibility →

Recruiting nowPhase 2

Semaglutide for Post-Smoking Cessation Weight Management

Obesity, OverweightCondition

semaglutide 2.4mg, PlaceboTreatment

United States2 locations

The University of Texas Health Science Center, HoustonSponsor

Updated 2026-02-11 · NCT06173778See eligibility →

Recruiting nowPhase 2

Metformin IN Asthma for Overweight and Obese Individuals (MINA)

Asthma, Asthma ChronicCondition

Metformin hydrochloride extended-release tablets, Visually identical placebo Metformin hydrochloride extended-release tabletsTreatment

United States2 locations

Johns Hopkins UniversitySponsor

Updated 2026-01-16 · NCT06273072See eligibility →

Recruiting nowNot applicable

Nurturing Needs Study: Parenting Food Motivated Children

Parenting, Eating BehaviorCondition

MeasurementTreatment

United States2 locations

Temple UniversitySponsor

Updated 2025-11-05 · NCT06111040See eligibility →

Recruiting nowNot applicable

Evaluating the Impact of a School-based Fruit and Vegetable Co-op on Cardiometabolic Child and Parents Health in a Persistent Poverty Area

Child Obesity, Cardiometabolic HealthCondition

Brighter BitesTreatment

United States1 locations

The University of Texas Health Science Center, HoustonSponsor

Updated 2025-07-08 · NCT06570707See eligibility →

Recruiting nowNot applicable

RESET System Pivotal Trial (Rev F)

Diabetes type2, ObesityCondition

RESET Liner, ShamTreatment

United States7 locations

Morphic Medical Inc.Sponsor

Updated 2024-07-18 · NCT04101669See eligibility →

Recruiting nowNot applicable

Endoscopic Sleeve Gastroplasty (ESG) for the Treatment of Obesity

Endoscopic Sleeve Gastroplasty, ObesityCondition

Endoscopic Sleeve Gastroplasty (ESG), Apollo OverStitch endoscopic suturing deviceTreatment

United States2 locations

The Methodist Hospital Research InstituteSponsor

Updated 2024-04-01 · NCT06339320See eligibility →

Opening soonPhase 2

A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer

Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaCondition

Medical Device Usage and Evaluation, TirzepatideTreatment

United States3 locations

National Cancer Institute (NCI)Sponsor

Updated 2026-08-26 · NCT07349641See eligibility →

Opening soonPhase 2

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Atherosclerosis, Cardiovascular DiseaseCondition

Clazakizumab, PlaceboTreatment

Argentina, Japan47 locations

Eli Lilly and CompanySponsor

Updated 2026-08-25 · NCT07783802See eligibility →

Opening soonPhase 3

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Overweight, ObesityCondition

Zenagamtide, SemaglutideTreatment

United States43 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07668414See eligibility →

Opening soonPhase 3

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

Argentina, Brazil56 locations

Novo Nordisk A/SSponsor

Updated 2026-05-28 · NCT07282613See eligibility →

Opening soonPhase 4

Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1

GLP - 1, Obesity & OverweightCondition

Semaglutide, Dietary CounselingTreatment

United States1 locations

William Marsh Rice UniversitySponsor

Updated 2026-04-28 · NCT07554417See eligibility →

Opening soonNot applicable

Brighter Bites/Legacy Produce Rx Program

Child ObesityCondition

Produce Prescription Group, Control GroupTreatment

United States1 locations

The University of Texas Health Science Center, HoustonSponsor

Updated 2025-01-10 · NCT06407284See eligibility →

Opening soonNot applicable

Small Changes Clinical Weight Loss Trial

ObesityCondition

Small Changes program, Standard behavioral therapy for weight lossTreatment

United States2 locations

The University of Texas Health Science Center, HoustonSponsor

Updated 2024-10-31 · NCT06668272See eligibility →

Invitation onlyNot applicable

Utilization of Airway Stabilizing Rod to Assist With Laryngeal Mask Airway Guided Fiberoptic Intubation in Adults With Obesity

Adult, Obesity, MorbidCondition

Fiberoptic Assisted Endotracheal Rod IntubationTreatment

United States1 locations

Baylor College of MedicineSponsor

Updated 2025-05-14 · NCT06916364See eligibility →

Active, not recruitingPhase 2

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Overweight, Type 2 DiabetesCondition

Petrelintide, PlaceboTreatment

United States48 locations

Zealand PharmaSponsor

Updated 2026-08-21 · NCT06926842See eligibility →

Active, not recruitingNot applicable

Long Term Outcomes of Bariatric Patients Treated With Surgery or Endoscopy

GERD, ObesityCondition

Endoscopy, SurgeryTreatment

United States6 locations

Johns Hopkins UniversitySponsor

Updated 2026-08-21 · NCT03705416See eligibility →

Active, not recruitingPhase 2

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

Obesity, OverweightCondition

RO7204239, RO7204239 Matching PlaceboTreatment

Poland, Spain35 locations

Hoffmann-La RocheSponsor

Updated 2026-08-11 · NCT06965413See eligibility →

Active, not recruitingNot applicable

Sleep and Physical Activity Intervention for Increasing Physical Activity in Overweight or Obese and Sedentary African Americans

Behavioral Disorder, Endocrine System DisorderCondition

Focus Group, Health EducationTreatment

United States2 locations

M.D. Anderson Cancer CenterSponsor

Updated 2026-08-10 · NCT04236882See eligibility →

Active, not recruitingPhase 2

A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

VRB-101, PlaceboTreatment

United States20 locations

Verdiva Bio Dev LimitedSponsor

Updated 2026-08-04 · NCT07553299See eligibility →

Active, not recruitingPhase 3

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

ObesityCondition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

United States46 locations

Novo Nordisk A/SSponsor

Updated 2026-07-24 · NCT07011667See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Obesity, OverweightCondition

Retatrutide, PlaceboTreatment

Argentina, Canada40 locations

Eli Lilly and CompanySponsor

Updated 2026-07-23 · NCT07035093See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

LY3841136, TirzepatideTreatment

Argentina, United States52 locations

Eli Lilly and CompanySponsor

Updated 2026-07-17 · NCT06603571See eligibility →

Active, not recruitingNot applicable

Parent and Family Oriented Support Interventions for the Facilitation of Weight Loss in African American Families

Obesity-Related Malignant NeoplasmCondition

Educational Activity, Educational InterventionTreatment

United States1 locations

M.D. Anderson Cancer CenterSponsor

Updated 2026-07-16 · NCT04644224See eligibility →

Active, not recruitingNot applicable

Parent and Family Obesity Intervention in Reducing Obesity Risk in Racial Ethnic Minority Families

Obesity-Related Malignant NeoplasmCondition

Behavioral Intervention, CounselingTreatment

United States1 locations

M.D. Anderson Cancer CenterSponsor

Updated 2026-07-16 · NCT05094466See eligibility →

Active, not recruitingPhase 2

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)Condition

Placebo, EnicepatideTreatment

Argentina, Canada70 locations

Carmot Therapeutics, Inc.Sponsor

Updated 2026-06-24 · NCT06628362See eligibility →

Active, not recruitingNot applicable

Efficacy Trial Healthy Dads, Healthy Kids for Hispanic Fathers and Children

Obesity, Obesity, ChildhoodCondition

Healthy Dads Healthy Kids, Standard of care controlTreatment

United States1 locations

Baylor College of MedicineSponsor

Updated 2026-04-29 · NCT05334420See eligibility →

Active, not recruitingPhase 2

Aleniglipron Phase 2 in Type 2 Diabetes Mellitus

Obese, ObesityCondition

Aleniglipron, PlaceboTreatment

United States16 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-04-27 · NCT07400588See eligibility →

This page shows the first 60 studies. Use the full search to filter all matches.

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Houston, United States

Current studies

Related cities